[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-small-cell-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-small-cell-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,77,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":48},"100489803","phase-2-a-study-of-targeted-radiation-therapy-in-people-with-non-small-cell-lung-cancer-nsclc-100489803",false,"NCT05657873","A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)","A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC","Inclusion Criteria:\n\n* Be greater than 18 years of age on day of signing informed consent.\n* Have a histologically confirmed diagnosis of stage IV NSCLC (includes patients who have progressed on durvalumab for Stage III NSCLC) without known mutations in (EGFR) or BRAF or rearrangements in ALK (anaplastic lymphoma kinase) or ROS-1.\n\n  o Patients with recurrent metastatic NSCLC following prior durvalumab for stage III disease are eligible provided this is their first immunotherapy course for metastatic disease (i.e., the planned anti-PD-(L)1-based regimen represents first-line systemic therapy in the metastatic setting).\n* Newly diagnosed metastatic non-small cell lung cancer (NSCLC), including both de novo and secondary metastatic disease, with one or more liver metastases\n* Plan to initiate standard of care anti-PD-(L)1 based immunotherapy +\u002F- platinum based chemotherapy for at least 3 cycles\n\n  o Regimens combining anti-CTLA-4 immunotherapy with anti-PD-1 (e.g., ipilimumab plus nivolumab) or anti-PD-L1 (e.g., tremelimumab plus durvalumab) immunotherapy are allowed.\n* Have a performance status of 0-2 on the ECOG Performance Scale.\n* Liver function tests:\n\n  * Total Bilirubin ≤ 1.5 x ULN\n  * AST\u002F ALT ≤ 5 x ULN\n* Eligible for L- SABR to all liver metastases as determined by the treating radiation oncologist\n* Patients with known HIV are eligible provided they are under treatment with effective anti-retroviral therapy with CD4 count \\>200 cells\u002Fmicroliter within 28 days prior to registration\n\nExclusion Criteria:\n\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen should be included.\n* Patients with prior external beam radiation therapy to the liver.\n* Patients with known active Hepatitis B or Hepatitis C.\n* Patients with immunosuppression including pharmacological immunosuppression with chronic steroids or immune modulators like cyclosporin or methotrexate and patients with active autoimmune disease.\n* Patients who are pregnant or breastfeeding\n* Men or women not using effective contraception.","ALL","18 Years",{"count":19,"type":20},68,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy\u002FL-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer\u002FNSCLC.",[26,27,28,29,30],"Non Small Cell Lung Cancer","Non Small Cell Lung Cancer Metastatic","Non-small Cell Carcinoma","NSCLC","NSCLC Stage IV",[32,27,28,33,34,29,30,35,36],"non small cell lung cancer","liver stereotactic ablative radiotherapy","L-SABR","Memorial Sloan Kettering Cancer Center","22-368","RECRUITING","2026-05-06",{"date":40,"type":41},"2026-05-07","ACTUAL",{"date":43,"type":41},"2022-12-09",{"date":45,"type":20},"2026-12-09",{"name":35,"class":47},"OTHER",9,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100604035","phase-3-a-study-to-learn-about-the-study-medicine-called-pf-08046054sgn-pdl1v-versus-docetaxel-in-adult-participants-with-previously-treated-programmed-cell-death-ligand-1-pd-l1-positive-non-small-cell-lung-cancer-nsclc-100604035","NCT07144280","A Study to Learn About the Study Medicine Called PF-08046054\u002FSGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054\u002FSGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","Inclusion Criteria\n\n* Histologically or cytologically confirmed diagnosis of NSCLC with locally advanced, unresectable Stage IIIB or IIIC not eligible for definitive chemoradiotherapy or metastatic (Stage IV: M1a, M1b, or M1c) disease per the American Joint Committee on Cancer (AJCC) Staging Manual, Version 8.0, and the Union for International Cancer Control (UICC) Staging System. Note: Participants with a neuroendocrine component or histology are not eligible.\n* PD-L1 expression on ≥1% of tumor cells based on local immunohistochemistry (IHC) testing with an assay utilizing the anti-PD-L1 monoclonal antibody clones 22C3 or SP263.\n* Participants who have NSCLC with known AGAs are permitted.\n* Able to provide any of the following tumor tissues for biomarker analysis:\n\n  * Archival specimen (preferably collected within 12 months after the last anticancer therapy) (see laboratory manual for details); or\n  * De novo biopsy from a tumor lesion, if medically feasible.\n* Participants must have received the following therapies and progressed during or relapsed after receiving their most recent prior therapy, or have been intolerant to their most recent therapy:\n\nParticipants with no known AGAs must fulfill 1 of the following conditions:\n\n* Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, and unless contraindicated, a PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).\n* Experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant, neoadjuvant, or chemoradiotherapy setting and received a PD-(L)1 monoclonal antibody at any time during the course of treatment.\n\nParticipants with known AGAs (eg, EGFR mutations, ALK translocations, or other relevant actionable mutations) must fulfill the following conditions:\n\n* Must have received at least 1 relevant AGA-targeted therapy if locally available and, in the opinion of the investigator, additional AGA-targeted therapy is not in the best interest of the participant\n* Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, or experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant, neoadjuvant, or chemoradiotherapy setting.\n* May have received PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).\n\nExclusion Criteria\n\n* History of another malignancy within 3 years before the first dose of PF-08046054, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year overall survival \\[OS\\] ≥90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.\n* Any central nervous system (CNS) lesions, unless definitively treated with CNS-directed local therapy (surgery and\u002For radiotherapy). Participants with definitively treated brain metastases are eligible if they meet the following criteria:\n\n  * The participant is on a stable dose of ≤10 mg\u002Fday of prednisone or equivalent for at least \\>14 days prior to randomization (if requiring steroid treatment).\n  * No clinical or radiographic progression in the CNS following CNS-directed definitive radiotherapy and\u002For surgery.\n  * Time since CNS-directed treatment is ≥28 days prior to randomization.\n* Participants with a history of leptomeningeal metastasis are excluded.\n* Prior treatment with an anti-PD-L1 agent (where indicated per protocol) within 5 half-lives.\n* Previous receipt of an MMAE-containing agent or prior docetaxel.\n\nThere are additional inclusion and exclusion criteria. The study center will determine if criteria for participations are met.",{"count":57,"type":20},680,[59],"PHASE3","The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation.\n\nParticipants will randomly (like a flip of the coin) be assigned to either the PF-08046054 treatment group or the docetaxel treatment group. Participants in the PF-08046054 treatment group will receive an IV infusion (injected directly into the veins) twice during each 21-day cycle. Participants in the docetaxel treatment group will receive an IV infusion once during each 21-day cycle. Study participation may be up to 5 years if the participant's NSCLC is responding to treatment. The study team will see how each participant is doing with the study treatment during regular visits at the clinic.",[28,62,63],"Non-Small Cell Lung Cancer Metastatic","Non-Small Cell Lung Carcinoma",[65,29],"Non-small cell lung cancer NSCLC","2026-04-20",{"date":68,"type":41},"2026-04-21",{"date":70,"type":41},"2025-09-29",{"date":72,"type":20},"2032-03-10",{"name":74,"class":75},"Pfizer","INDUSTRY",305,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100497077","phase-1-study-to-determine-the-safety-and-pharmacokinetics-of-do-2-in-patients-with-advanced-or-refractory-solid-tumours-100497077","NCT05752552","Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours","A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET Kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours","Inclusion Criteria:\n\n* 18 years or older\n* histologically or cytologically confirmed locally advanced, unresectable or metastatic NSCLC, no longer eligible for approved, available standard therapies. To be entered patients must have proven MET exon 14 skipping mutation, determined by local next generation sequencing (NGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS) or other genomic analysis methods, from an assessment not older than 3 months\n* measurable disease in accordance with RECIST 1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n* adequate bone marrow function, without the support of cytokines\n* adequate liver function\n* adequate renal function with serum creatinine \\\u003C1 x institutional UNL and GFR within normal range\n* agree to follow the contraception requirements of the trial\n* signed informed consent, indicating study patients understand the purpose of and procedures required for the study and are willing to participate in the study.\n\nExclusion Criteria:\n\n* tumour harbouring other known oncogenic mutations promoting tumour growth\n* major surgery within 3 weeks before enrolment\n* chemotherapy (in the case of nitrosoureas and mitomycin C within 6 weeks), radiotherapy, immunotherapy, or any other study drug within 3 weeks before study drug administration\n* antibody based cancer therapy within 4 weeks before administration of the first dose of DO-2\n* patients who became progressive on previous treatment with a MET-kinase inhibitor\n* patients with brain metastases are excluded unless all of the following criteria are met:\n\n  1. CNS lesions are asymptomatic and previously treated\n  2. No ongoing requirement for corticosteroids as therapy for CNS metastases\n  3. Imaging demonstrates stability of disease \\> 28 days from last treatment for CNS metastases\n* leptomeningeal involvement (leptomeningeal carcinomatosis)\n* history of uncontrolled heart disease including unstable angina, congestive heart failure, myocardial infarction within preceding 12 months, clinically significant rhythm or conduction abnormality, congenital long QT syndrome, obligate use of a cardiac pacemaker, QTc at screening greater than 450 milliseconds in males and greater than 470 milliseconds in females\n* uncontrolled arterial hypertension despite appropriate therapy\n* positive pregnancy test (urinary beta-hCG) at screening (applicable to women of child-bearing potential who are sexually active)\n* mental status alteration or history of major psychiatric illness, which may potentially impair patient's compliance with study procedures\n* signs and symptoms of active infection requiring systemic therapy\n* other medical condition (e.g. pre-existing kidney dysfunction) that in the opinion of the investigator makes it undesirable for a patient to participate\n* inability or unwillingness to swallow capsules and malabsorption syndrome or other condition that would interfere with enteral absorption",{"count":85,"type":20},55,[87],"PHASE1","This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative. The dose escalation is completed, Part 2 of the study is ongoing.",[90,91,92,93,28,94,95],"Adult Solid Tumor","Advanced Solid Tumor","Refractory Tumor","Non-small Cell Lung Cancer","Lung Cancer","Hereditary Renal Papillary Cancer","2026-03-30",{"date":98,"type":41},"2026-04-03",{"date":100,"type":41},"2022-12-20",{"date":102,"type":20},"2028-09",{"name":104,"class":75},"DeuterOncology",13,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100520530","physical-activity-coaching-after-surgery-for-patients-with-resectable-non-small-cell-lung-cancer-100520530","NCT06057766","Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer","Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer: a Randomized Controlled Trial","LucaMove","Inclusion Criteria:\n\n* Resectable (I-IIIA) NSCLC patients who had lung resection surgery, one to twelve months before inclusion, with or without (neo-)adjuvant chemotherapy\u002Fradiotherapy\u002Fimmunotherapy.\n* If patients received adjuvant chemotherapy\u002Fradiotherapy, the inclusion window is one months to twelve months after the end of adjuvant chemotherapy\u002Fradiotherapy.\n* If patients receive adjuvant immunotherapy after the end of adjuvant chemotherapy, patients can be included during the immunotherapy.\n* Adults (18+ year)\n* Patients who do not systematically perform structured exercise or are planned to do so.\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Patients having progressive or recurrent lung cancer\n* Patients who had other malignancies in the last 2 years\n* Psychiatric disorders that preclude them from participation in a physical activity intervention and\u002For performing the test battery\n* Unable to learn to work with a new electronic device (e.g. smartphone)\n* Not understanding and speaking Dutch\n* Patients with comorbidities or other treatments that preclude them from participation in a physical activity intervention and\u002For performing the test battery",{"count":115,"type":20},90,[117],"NA","The goal of this randomized controlled clinical trial is to test a 12-week physical activity telecoaching program for NSCLC patients after surgery.\n\nThe main question it aims to answer is:\n\nWhat is the effectiveness and acceptability of a 12-week (semi)automated low-to-moderate intensity PA tele coaching program on physical activity (mean steps per day) in resectable (stage I-IIIA) NSCLC patients after lung surgery, as compared to usual care?\n\nPatients with NSCLC will be enrolled in the study from 1 month postoperatively up to 1 year postoperatively. They will be randomized in either the intervention group or the control group.\n\nPatients randomized in the intervention group will be asked to enter a 12-week physical activity telecoaching program with the aim to enhance their physical activity. The telecoaching programs consists of 4 pilars:\n\n1. A wearable (Fitbit) to measure and give feedback on their daily step count.\n2. A smartphone coaching application, installed on a smartphone and linked to the wearable, providing automated coaching by displaying an individual activity goal (expressed as daily step count) and daily and weekly feedback on the performance (steps) of the patient.\n3. A one-to-one semi-structured interview with the coach discussing the importance of physical activity, motivation, self-efficacy, barriers, favourite activities, and (coping) strategies to become more active resulting in an individual action plan.\n4. Phone calls by the coaches initiated in pre-defined situations (non-compliance with wearing the step counter, failure to transmit the data, failure to progress).\n\nPatients randomized in the control group will remain their usual care and will not enter the 12-week physical activity telecoaching program.",[26,28],[121,122,123,124],"Surgery","Physical activity","coaching","telecoaching","2025-11-14",{"date":127,"type":41},"2025-11-18",{"date":129,"type":41},"2024-01-01",{"date":131,"type":20},"2026-09-01",{"name":133,"class":47},"University Hospital, Ghent",6]